Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Count me in the .. buying at .50 and waiting for 1.00 crowd here. :)
Thanks for quick reply.
Have a great week $$
They ususally bounce back in upto 2 weeks. I would sell at around .97
i got in today at 0.5 for the bounce up.
Where will it go this week.
Predictions?
These biotechs ususally bounce the 2nd or third day after a crash. Just buy in blocks in the way down and on the way up. Not complicated.
Today sucks big time.
Bad drug trial
Mon Mar 12 08:00:12 2018 EDT
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)
Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)
Further development of Sollpura to be discontinued
Anthera to evaluate all strategic alternatives
Anthera to host teleconference today at 8:30 am ET
HAYWARD, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) announced today that Sollpura did not meet the non-inferiority margin of the CFA primary endpoint in the RESULT Phase 3 clinical study of exocrine pancreatic insufficiency (“EPI”) due to cystic fibrosis.
The design of the RESULT study was based on the outcome of the previous Phase 3 SOLUTION study and included a higher starting dose and more aggressive dose optimizations based on clinical signs and symptoms of malabsorption. In the RESULT study, all patients randomized to Sollpura received a starting dose that was approximately 25% higher than their pre-study porcine pancreatic enzyme replacement therapy (“PERT”) dose and 59% of subjects received further dose adjustments, yielding a mean Sollpura dose (8,673 [range 2,925 – 14,941 lipase units/kg/day]) that was both substantially higher than the comparator Pancreaze mean dose (6527 [range 2358 - 10253 units/kg/day]) and higher than the Sollpura dose in the previous SOLUTION study (mean dose of 7,286 [range 4478 - 10000 units/kg/day]). Although a proportion of patients randomized to Sollpura maintained or improved their CFA from baseline, a higher proportion of patients experienced a worsening. The mean treatment difference in CFA change from baseline was 14.3%, with upper and lower 95% confidence intervals of -18.22 and -10.39. In contrast, the treatment difference in CNA change from baseline (-1.53%) was well within the 15% non-inferiority margin. In comparison to the earlier SOLUTION study, the presence or absence of concomitant gastric acid suppressants had no meaningful effect on CFA (mean changes from baseline in CFA of -15.06% and -16.58%, respectively).
“We are greatly disappointed by the findings of the RESULT study,” shared Craig Thompson , President & CEO. “We would like to extend our deepest gratitude to the patients and their families, study investigators, and the cystic fibrosis community for the support they have provided in the clinical development of Sollpura.”
Anthera Pharmaceuticals, Inc. plans to evaluate the full data outputs and will suspend further clinical development of Sollpura, including the 20-Week Extension Period of RESULT, the SIMPLICITY study in patients ages 28 days to <7 years which was designed to assess Sollpura powder for oral solution, and the EASY study which was designed to follow the long-term safety of patients on Sollpura. In addition, Anthera Pharmaceuticals, Inc. plans to evaluate all strategic alternatives in order to maximize shareholder value.
Conference Call Details
What is going on here
I warned shareholders over a week ago that the spike was bogus. I played this stock pre RS last year. I am sure they will go for another RS before summer if they can pull it off. GLTA :)
ANTH we flop around here until next week run.Is my guess.Watch for good dip to buy.
Lol that is ftr!
Just the letter you left out
No middle letter.
Just post the letter here
Sorry no pm. Frontier communication. I'm at work right. I'll be day trading in few months.
ANTH Print the single letter you left out of a stock you mentioned.
Yeah!! Waiting for my founds to clears I can add more.
ANTH Looking like over 3.00 soon.Bid and ask building
ANTH might go over $3.00 today
Looking good here. I'll be adding next week.
ANTH There's the 2.90 Iwas talking about
ANTH WOW flippers are getting their faces punched off.
ANTH flippers are here.They will be crushed.imo
WOW another options bid and ask jump up.TODAY?
ANTH Resistance NOW SHES GONE GONE GONE!!!!!
ANTH 2.88 new resistance going going going
WE broke resistance.Shorts about to get KILLED imo
Shorts are trying to keep this down.
Im in FT%R already up 7% today
I'm in. IMOO EASY TRIPPLE FROM HERE.
ANTH INVESTOR 86 are you watching?Blew by resistance
ANTH OPTIONS BIDS & ASKS JUMPING.That's where the money is.
ANTH 13.8 Mill OUSTANDING 10.1 Million float
ANTH short term med term and long term expected results https://www.barchart.com/stocks/quotes/ANTH/opinion
GO long with options https://ih.advfn.com/p.php?pid=nmona&article=76866912
ANTH Company Summary
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
F
ANTH good news https://ih.advfn.com/p.php?pid=nmona&article=76022688
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2495
|
Created
|
03/01/10
|
Type
|
Free
|
Moderators |
Anthera Pharmaceuticals Inc.
Nasdaq: ANTH
Contact Info
25801 Industrial Blvd, Suite B • Hayward, CA 94545
Press Contact: pr@anthera.com
Business Development: bd@anthera.com
Vendors: ap@anthera.com
Website: www.anthera.com
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...
http://finance.yahoo.com/q?s=ANTH
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,
including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into
PHASE 3
Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),
now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment
of lupus.
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous
countries by year's end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.
The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as
it currently has more desirable features than that of Benlysta.
Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a
series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to
specific patient populations and has not been studied in combination with other biologics.
These attributes of blisibimod including a different mechanism of action, will set it apart from
Benlysta, Global Data concludes.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |